Last update :
27/11/2024
Anticancer drug   Eribulin mesylate  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Elefix Argentina
Halaven Argentina, Belgium, Brazil, Canada, Chile, Denmark, Finland, France, Germany, Great Britain, Hungary, Iceland, Ireland, Italy, Japan, Luxembourg, Malaysia, Mexico, Norway, Peru, Romania, Slovenia, Spain, Sweden, Switzerland
References   injection   References : Eribulin mesylate  
Type Publication
3250 Manufacturer Eribulin (Halaven®) - Summary of Product Characteristics.
Eisai Ltd 2011
3331 Journal Poujol S, Dell'ova M, Bekhtari K, Bressolle F, Pinguet F.
Stability of the ready-to-use solutions of eribulin for intravenous infusion.
Ann Pharm Fr 2012 ; 70, 5: 249-255.
3707 Journal Spindeldreier K, Thiesen J, Lipp H.P, Krämer I.
Physico-chemical stability of eribulin mesylate containing concentrate and ready-to-administer solutions.
J Oncol Pharm Practice 2014 ; 20: 183-189

  Mentions Légales